Marine resources have tremendous potential for developing high-value biomaterials. The
last decade has seen an increasing number of biomaterials that originate from marine …

PURPOSE Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-
based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited …

For nearly 50 years, immunotherapy has been used in patients with bladder cancer in the
form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still the first-line …

Bladder cancer is the ninth most frequently diagnosed cancer world-wide and ranks 13th in
cancer-related deaths. Two tremendous breakthroughs in bladder cancer therapy over the …

The fact that there are now five immune checkpoint inhibitor (ICI) monoclonal antibodies
approved since 2016 that target programmed cell death protein 1 or programmed death …

Simple Summary For metastatic urothelial cancer (UC), platinum-based chemotherapy and
immunotherapy are used, with newer treatments like monoclonal antibodies (eg …

Bladder cancer is common worldwide, with most patients presenting with nonmuscle
invasive disease. Multiple intravesical recurrences lead to reduced quality of life and high …

Immunotherapy has been well regarded as one of the safer and antigen-specific anti-cancer
treatments compared to first-generation chemotherapy. Since Coley's discovery, researchers …

Antibody-drug conjugates offer the possibility of directing powerful cytotoxic agents to a
malignant tumor while sparing normal tissue. The challenge is to select an antibody target …

Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA
approvals in the last two years and a projected market value of over $4 billion by 2024 …